MediPal Holdings Corporation
MediPal Holdings Corporation (MEPDF) Stock Competitors & Peer Comparison
See (MEPDF) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Distribution Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| MEPDF | $19.00 | +0.00% | 3.9B | 15.45 | $1.23 | +2.19% |
| SHPMF | $1.46 | +0.00% | 8.5B | 6.64 | $0.22 | +3.81% |
| SHTDF | $2.68 | +0.00% | 8.4B | 8.65 | $0.31 | +3.51% |
| SHTDY | $13.00 | +0.12% | 8.1B | 7.83 | $1.66 | +2.72% |
| GALNF | $116.19 | +0.00% | 5.8B | 24.99 | $4.65 | +2.47% |
| SHPMY | $7.60 | +0.00% | 5.6B | 6.85 | $1.11 | +3.44% |
| CAKFY | $4.10 | +0.00% | 5.4B | -68.33 | -$0.06 | N/A |
| MAHLY | $19.10 | +8.06% | 3.9B | 15.53 | $1.23 | +1.85% |
| ALFRY | $16.81 | +3.61% | 3.1B | 19.78 | $0.85 | +1.36% |
| AMFPF | $10.09 | +0.00% | 2.2B | 21.46 | $0.47 | +3.23% |
Stock Comparison
MEPDF vs SHPMF Comparison April 2026
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.9B. In comparison, SHPMF has a market cap of 8.5B. Regarding current trading prices, MEPDF is priced at $19.00, while SHPMF trades at $1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 15.45, whereas SHPMF's P/E ratio is 6.64. In terms of profitability, MEPDF's ROE is +0.07%, compared to SHPMF's ROE of +0.08%. Regarding short-term risk, MEPDF and SHPMF have similar daily volatility (0.00).Check SHPMF's competition here
MEPDF vs SHTDF Comparison April 2026
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.9B. In comparison, SHTDF has a market cap of 8.4B. Regarding current trading prices, MEPDF is priced at $19.00, while SHTDF trades at $2.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 15.45, whereas SHTDF's P/E ratio is 8.65. In terms of profitability, MEPDF's ROE is +0.07%, compared to SHTDF's ROE of +0.09%. Regarding short-term risk, MEPDF and SHTDF have similar daily volatility (0.00).Check SHTDF's competition here
MEPDF vs SHTDY Comparison April 2026
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.9B. In comparison, SHTDY has a market cap of 8.1B. Regarding current trading prices, MEPDF is priced at $19.00, while SHTDY trades at $13.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 15.45, whereas SHTDY's P/E ratio is 7.83. In terms of profitability, MEPDF's ROE is +0.07%, compared to SHTDY's ROE of +0.09%. Regarding short-term risk, MEPDF is less volatile compared to SHTDY. This indicates potentially lower risk in terms of short-term price fluctuations for MEPDF.Check SHTDY's competition here
MEPDF vs GALNF Comparison April 2026
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.9B. In comparison, GALNF has a market cap of 5.8B. Regarding current trading prices, MEPDF is priced at $19.00, while GALNF trades at $116.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 15.45, whereas GALNF's P/E ratio is 24.99. In terms of profitability, MEPDF's ROE is +0.07%, compared to GALNF's ROE of +0.12%. Regarding short-term risk, MEPDF is less volatile compared to GALNF. This indicates potentially lower risk in terms of short-term price fluctuations for MEPDF.Check GALNF's competition here
MEPDF vs SHPMY Comparison April 2026
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.9B. In comparison, SHPMY has a market cap of 5.6B. Regarding current trading prices, MEPDF is priced at $19.00, while SHPMY trades at $7.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 15.45, whereas SHPMY's P/E ratio is 6.85. In terms of profitability, MEPDF's ROE is +0.07%, compared to SHPMY's ROE of +0.08%. Regarding short-term risk, MEPDF and SHPMY have similar daily volatility (0.00).Check SHPMY's competition here
MEPDF vs CAKFY Comparison April 2026
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.9B. In comparison, CAKFY has a market cap of 5.4B. Regarding current trading prices, MEPDF is priced at $19.00, while CAKFY trades at $4.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 15.45, whereas CAKFY's P/E ratio is -68.33. In terms of profitability, MEPDF's ROE is +0.07%, compared to CAKFY's ROE of -0.02%. Regarding short-term risk, MEPDF and CAKFY have similar daily volatility (0.00).Check CAKFY's competition here
MEPDF vs MAHLY Comparison April 2026
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.9B. In comparison, MAHLY has a market cap of 3.9B. Regarding current trading prices, MEPDF is priced at $19.00, while MAHLY trades at $19.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 15.45, whereas MAHLY's P/E ratio is 15.53. In terms of profitability, MEPDF's ROE is +0.07%, compared to MAHLY's ROE of +0.07%. Regarding short-term risk, MEPDF and MAHLY have similar daily volatility (0.00).Check MAHLY's competition here
MEPDF vs ALFRY Comparison April 2026
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.9B. In comparison, ALFRY has a market cap of 3.1B. Regarding current trading prices, MEPDF is priced at $19.00, while ALFRY trades at $16.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 15.45, whereas ALFRY's P/E ratio is 19.78. In terms of profitability, MEPDF's ROE is +0.07%, compared to ALFRY's ROE of +0.07%. Regarding short-term risk, MEPDF and ALFRY have similar daily volatility (0.00).Check ALFRY's competition here
MEPDF vs AMFPF Comparison April 2026
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.9B. In comparison, AMFPF has a market cap of 2.2B. Regarding current trading prices, MEPDF is priced at $19.00, while AMFPF trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 15.45, whereas AMFPF's P/E ratio is 21.46. In terms of profitability, MEPDF's ROE is +0.07%, compared to AMFPF's ROE of +0.09%. Regarding short-term risk, MEPDF is less volatile compared to AMFPF. This indicates potentially lower risk in terms of short-term price fluctuations for MEPDF.Check AMFPF's competition here
MEPDF vs ARHCF Comparison April 2026
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.9B. In comparison, ARHCF has a market cap of 2.2B. Regarding current trading prices, MEPDF is priced at $19.00, while ARHCF trades at $11.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 15.45, whereas ARHCF's P/E ratio is 9.97. In terms of profitability, MEPDF's ROE is +0.07%, compared to ARHCF's ROE of +0.07%. Regarding short-term risk, MEPDF and ARHCF have similar daily volatility (0.00).Check ARHCF's competition here
MEPDF vs SZUKF Comparison April 2026
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.9B. In comparison, SZUKF has a market cap of 1.7B. Regarding current trading prices, MEPDF is priced at $19.00, while SZUKF trades at $30.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 15.45, whereas SZUKF's P/E ratio is 11.43. In terms of profitability, MEPDF's ROE is +0.07%, compared to SZUKF's ROE of +0.09%. Regarding short-term risk, MEPDF and SZUKF have similar daily volatility (0.00).Check SZUKF's competition here
MEPDF vs MEDOF Comparison April 2026
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.9B. In comparison, MEDOF has a market cap of 1.2B. Regarding current trading prices, MEPDF is priced at $19.00, while MEDOF trades at $50.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 15.45, whereas MEDOF's P/E ratio is 73.53. In terms of profitability, MEPDF's ROE is +0.07%, compared to MEDOF's ROE of +0.04%. Regarding short-term risk, MEPDF is less volatile compared to MEDOF. This indicates potentially lower risk in terms of short-term price fluctuations for MEPDF.Check MEDOF's competition here
MEPDF vs IUSDF Comparison April 2026
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.9B. In comparison, IUSDF has a market cap of 997.7M. Regarding current trading prices, MEPDF is priced at $19.00, while IUSDF trades at $14.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 15.45, whereas IUSDF's P/E ratio is 18.42. In terms of profitability, MEPDF's ROE is +0.07%, compared to IUSDF's ROE of +0.13%. Regarding short-term risk, MEPDF and IUSDF have similar daily volatility (0.00).Check IUSDF's competition here
MEPDF vs ARRJF Comparison April 2026
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.9B. In comparison, ARRJF has a market cap of 807.6M. Regarding current trading prices, MEPDF is priced at $19.00, while ARRJF trades at $2.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 15.45, whereas ARRJF's P/E ratio is 22.81. In terms of profitability, MEPDF's ROE is +0.07%, compared to ARRJF's ROE of +0.04%. Regarding short-term risk, MEPDF is less volatile compared to ARRJF. This indicates potentially lower risk in terms of short-term price fluctuations for MEPDF.Check ARRJF's competition here
MEPDF vs EXHI Comparison April 2026
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.9B. In comparison, EXHI has a market cap of 16M. Regarding current trading prices, MEPDF is priced at $19.00, while EXHI trades at $0.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 15.45, whereas EXHI's P/E ratio is N/A. In terms of profitability, MEPDF's ROE is +0.07%, compared to EXHI's ROE of +0.00%. Regarding short-term risk, MEPDF is less volatile compared to EXHI. This indicates potentially lower risk in terms of short-term price fluctuations for MEPDF.Check EXHI's competition here
MEPDF vs PDRX Comparison April 2026
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.9B. In comparison, PDRX has a market cap of 5.7M. Regarding current trading prices, MEPDF is priced at $19.00, while PDRX trades at $3.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 15.45, whereas PDRX's P/E ratio is 3.08. In terms of profitability, MEPDF's ROE is +0.07%, compared to PDRX's ROE of -0.02%. Regarding short-term risk, MEPDF is less volatile compared to PDRX. This indicates potentially lower risk in terms of short-term price fluctuations for MEPDF.Check PDRX's competition here
MEPDF vs NSVGF Comparison April 2026
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.9B. In comparison, NSVGF has a market cap of 3.3M. Regarding current trading prices, MEPDF is priced at $19.00, while NSVGF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 15.45, whereas NSVGF's P/E ratio is -1.00. In terms of profitability, MEPDF's ROE is +0.07%, compared to NSVGF's ROE of +0.21%. Regarding short-term risk, MEPDF and NSVGF have similar daily volatility (0.00).Check NSVGF's competition here
MEPDF vs KOSK Comparison April 2026
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.9B. In comparison, KOSK has a market cap of 2.3M. Regarding current trading prices, MEPDF is priced at $19.00, while KOSK trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 15.45, whereas KOSK's P/E ratio is -0.18. In terms of profitability, MEPDF's ROE is +0.07%, compared to KOSK's ROE of -0.14%. Regarding short-term risk, MEPDF is less volatile compared to KOSK. This indicates potentially lower risk in terms of short-term price fluctuations for MEPDF.Check KOSK's competition here
MEPDF vs ITNS Comparison April 2026
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.9B. In comparison, ITNS has a market cap of 609.4K. Regarding current trading prices, MEPDF is priced at $19.00, while ITNS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 15.45, whereas ITNS's P/E ratio is -0.04. In terms of profitability, MEPDF's ROE is +0.07%, compared to ITNS's ROE of +0.01%. Regarding short-term risk, MEPDF is less volatile compared to ITNS. This indicates potentially lower risk in terms of short-term price fluctuations for MEPDF.Check ITNS's competition here
MEPDF vs ENMI Comparison April 2026
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.9B. In comparison, ENMI has a market cap of 383.1K. Regarding current trading prices, MEPDF is priced at $19.00, while ENMI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 15.45, whereas ENMI's P/E ratio is -0.01. In terms of profitability, MEPDF's ROE is +0.07%, compared to ENMI's ROE of +0.17%. Regarding short-term risk, MEPDF and ENMI have similar daily volatility (0.00).Check ENMI's competition here
MEPDF vs CHME Comparison April 2026
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.9B. In comparison, CHME has a market cap of 239.5K. Regarding current trading prices, MEPDF is priced at $19.00, while CHME trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 15.45, whereas CHME's P/E ratio is -1.01. In terms of profitability, MEPDF's ROE is +0.07%, compared to CHME's ROE of +0.04%. Regarding short-term risk, MEPDF is less volatile compared to CHME. This indicates potentially lower risk in terms of short-term price fluctuations for MEPDF.Check CHME's competition here
MEPDF vs PHRX Comparison April 2026
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.9B. In comparison, PHRX has a market cap of 5.2K. Regarding current trading prices, MEPDF is priced at $19.00, while PHRX trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 15.45, whereas PHRX's P/E ratio is N/A. In terms of profitability, MEPDF's ROE is +0.07%, compared to PHRX's ROE of +0.85%. Regarding short-term risk, MEPDF is less volatile compared to PHRX. This indicates potentially lower risk in terms of short-term price fluctuations for MEPDF.Check PHRX's competition here
MEPDF vs MLTO Comparison April 2026
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.9B. In comparison, MLTO has a market cap of 1.7K. Regarding current trading prices, MEPDF is priced at $19.00, while MLTO trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 15.45, whereas MLTO's P/E ratio is -0.00. In terms of profitability, MEPDF's ROE is +0.07%, compared to MLTO's ROE of N/A. Regarding short-term risk, MEPDF is less volatile compared to MLTO. This indicates potentially lower risk in terms of short-term price fluctuations for MEPDF.Check MLTO's competition here
MEPDF vs TGVN Comparison April 2026
MEPDF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, MEPDF stands at 3.9B. In comparison, TGVN has a market cap of 120. Regarding current trading prices, MEPDF is priced at $19.00, while TGVN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
MEPDF currently has a P/E ratio of 15.45, whereas TGVN's P/E ratio is -0.00. In terms of profitability, MEPDF's ROE is +0.07%, compared to TGVN's ROE of N/A. Regarding short-term risk, MEPDF and TGVN have similar daily volatility (0.00).Check TGVN's competition here